Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway

被引:360
作者
Nguyen, Kim-Son H. [1 ]
Kobayashi, Susumu [1 ]
Costa, Daniel B. [1 ]
机构
[1] Harvard Univ, Div Hematol Oncol, Beth Israel Deaconess Med Ctr, Dept Med,Sch Med, Boston, MA 02215 USA
关键词
BIBW; 2992; D761Y; Gefitinib; ErbB3; Erlotinib; HKI-272; L747S; MET; PF-00299804; T790M; XL647; PROSPECTIVE PHASE-II; GENE COPY NUMBER; GEFITINIB TREATMENT; EGF RECEPTOR; ANTITUMOR-ACTIVITY; TREATED PATIENTS; DRUG-RESISTANCE; T790M MUTATIONS; SUPPORTIVE CARE; C-MET;
D O I
10.3816/CLC.2009.n.039
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Most advanced non-small-cell lung cancers (NSCLCs) with activating epidermal growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. However, over time (median of 6-12 months), most tumors develop acquired resistance to EGFR TKIs. Intense research in these NSCLCs has identified two major mechanisms of resistance to gefitinib/erlotinib: secondary resistance mutations and "oncogene kinase switch" systems. The secondary T790M mutation occurs in 50% of EGFR-mutated patients with TKI resistance, and in vitro, this mutation negates the hypersensitivity of activating EGFR mutations. Sensitive detection methods have identified a proportion of TKI-naive tumors that carry T790M, and these resistant clones may be selected after exposure to gefitinib or erlotinib. Other secondary resistance mutations (D761Y, L747S, T854A) seem to be rare. The amplification of the MET oncogene is present in 20% of TKI-resistant tumors; however, in half of the cases with this "oncogene kinase switch" mechanism the T790M is coexistent. It is possible that other kinases (such as insulin-like growth factor-1 receptor [IGF-1R]) might also be selected to bypass EGFR pathways in resistant tumors. The growing preclinical data in EGFR-mutated NSCLCs with acquired resistance to gefitinib or erlotinib has spawned the initiation or conception of clinical trials testing novel EGFR inhibitors that in vitro inhibit T790M (neratinib, XL647, BIBW 2992, and PF-00299804), MET, or IGF-1R inhibitors in combination with EGFR TKIs, and heat shock protein 90 inhibitors. Ongoing preclinical and clinical research in EGFR-mutated NSCLC has the potential to significantly improve the outcomes of patients with these somatic mutations.
引用
收藏
页码:281 / 289
页数:9
相关论文
共 94 条
  • [31] Chronic myeloid leukaemia
    Hehlmann, Ruediger
    Hochhous, Andreas
    Baccarani, Michele
    [J]. LANCET, 2007, 370 (9584) : 342 - 350
  • [32] Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
    Hidalgo, M
    Siu, LL
    Nemunaitis, J
    Rizzo, J
    Hammond, LA
    Takimoto, C
    Eckhardt, SG
    Tolcher, A
    Britten, CD
    Denis, L
    Ferrante, K
    Von Hoff, DD
    Silberman, S
    Rowinsky, EK
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) : 3267 - 3279
  • [33] Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations
    Inoue, Akira
    Suzuki, Takuji
    Fukuhara, Tatsuro
    Maemondo, Makoto
    Kimura, Yuichiro
    Morikawa, Naoto
    Watanabe, Hiroshi
    Saijo, Yasuo
    Nukiwa, Toshihiro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (21) : 3340 - 3346
  • [34] Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours
    Jaenne, Pasi A.
    [J]. LUNG CANCER, 2008, 60 : S3 - S9
  • [35] JANNE PA, 2008, J CLIN ONCOL S, V26, pS430
  • [36] Cancer statistics, 2008
    Jemal, Ahmedin
    Siegel, Rebecca
    Ward, Elizabeth
    Hao, Yongping
    Xu, Jiaquan
    Murray, Taylor
    Thun, Michael J.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2008, 58 (02) : 71 - 96
  • [37] The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
    Ji, Hongbin
    Li, Danan
    Chen, Liang
    Shimamura, Takeshi
    Kobayashi, Susumu
    McNamara, Kate
    Mahmood, Umar
    Mitchell, Albert
    Sun, Yangping
    Al-Hashem, Ruclayyah
    Chirieac, Lucian R.
    Padera, Robert
    Bronson, Roderick T.
    Kim, William
    Janne, Pasi A.
    Shapiro, Geoffrey I.
    Tenen, Daniel
    Johnson, Bruce E.
    Weissleder, Ralph
    Sharpless, Norman E.
    Wong, Kwok-Kin
    [J]. CANCER CELL, 2006, 9 (06) : 485 - 495
  • [38] RETRACTED: Phase II Study of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non-Small-Cell Lung Cancer (Retracted article. See vol. 30, pg. 4179, 2012)
    Karp, Daniel D.
    Paz-Ares, Luis G.
    Novello, Silvia
    Haluska, Paul
    Garland, Linda
    Cardenal, Felipe
    Blakely, L. Johnetta
    Eisenberg, Peter D.
    Langer, Corey J.
    Blumenschein, George, Jr.
    Johnson, Faye M.
    Green, Stephanie
    Gualberto, Antonio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) : 2516 - 2522
  • [39] An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor
    Kobayashi, S
    Ji, HB
    Yuza, Y
    Meyerson, M
    Wong, KK
    Tenen, DG
    Halmos, B
    [J]. CANCER RESEARCH, 2005, 65 (16) : 7096 - 7101
  • [40] EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
    Kobayashi, S
    Boggon, TJ
    Dayaram, T
    Janne, PA
    Kocher, O
    Meyerson, M
    Johnson, BE
    Eck, MJ
    Tenen, DG
    Halmos, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) : 786 - 792